NLS Pharmaceutics AG announced an update to its merger and reorganization plans with Kadimastem Ltd. and NLS Pharmaceuticals (Israel) Ltd. The Fourth Amendment to the Agreement of Merger and Plan of Reorganization, dated June 5, 2025, outlines changes to the terms of the merger. Key amendments include updates to the calculation of the merger consideration, with detailed provisions for estimating closing indebtedness, cash, and adjusted cash amounts by NLS Pharmaceutics. The updated agreement reflects the collaborative efforts of the involved parties to ensure a smooth transition and integration process.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。